Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: gemtuzumab ozogamicin, Celltech Group.

I Niculescu-Duvaz1

  • 1CRC Centre for Cancer Therapeutics, Institute for Cancer Research, Sutton, Surrey, SM2 5NG, UK. ion@icr.ac.uk

Current Opinion in Molecular Therapeutics
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Development of an outpatient finger-prick glomerular filtration rate procedure suitable for epidemiological studies.

Kidney international·2006
Same author

NCI-EORTC-AACR--11th Symposium on New Drugs in Cancer Therapy: Gene therapy and new drugs. 7-10 November 2000, Amsterdam, The Netherlands.

IDrugs : the investigational drugs journal·2005
Same author

Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.

Journal of medicinal chemistry·2004
Same author

Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer.

Current opinion in molecular therapeutics·2001
Same author

Thymitaq (Zarix).

Current opinion in investigational drugs (London, England : 2000)·2001
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Gemtuzumab ozogamicin, a targeted therapy for acute myeloid leukemia (AML), received FDA approval for relapsed patients. This antibody-drug conjugate offers a new treatment option for elderly AML patients ineligible for chemotherapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Immunotherapy

Background:

  • Acute myeloid leukemia (AML) is a significant hematologic malignancy.
  • Treatment of relapsed AML, particularly in elderly patients, remains a challenge.
  • Targeted therapies offer a promising approach to overcome chemotherapy resistance.

Purpose of the Study:

  • To evaluate the efficacy and safety of Gemtuzumab ozogamicin (CMA-676) for treating acute myeloid leukemia.
  • To secure regulatory approval for Gemtuzumab ozogamicin as a treatment for relapsed AML patients.

Main Methods:

  • Gemtuzumab ozogamicin (CMA-676) is a novel antibody-drug conjugate.
  • It comprises a cytotoxic calicheamicin payload linked to a CD33-targeting humanized monoclonal antibody.
  • Submitted for US FDA approval for relapsed AML patients.

Related Experiment Videos

Main Results:

  • FDA granted Priority Review status in January 2000.
  • FDA's Oncologic Drugs Advisory Committee recommended accelerated approval in March 2000.
  • Final FDA approval was granted in May 2000 for specific patient populations.

Conclusions:

  • Gemtuzumab ozogamicin (Mylotarg) was approved for elderly patients (60+) with relapsed CD33+ AML not eligible for cytotoxic chemotherapy.
  • The drug was launched in the US in June 2000.
  • Potential for first-line therapy and significant market projections indicate therapeutic promise.